Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 26

Sort by

Sort Order Select

Journal Articles

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clin Cancer Res OF1–OF14.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-4256

Published: 26 May 2022

View article

Includes: Supplementary data

Journal Articles

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Clin Cancer Res (2021) 27 (24): 6666–6676.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1504

Published: 15 December 2021

View article

Includes: Supplementary data

Journal Articles

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clin Cancer Res (2021) 27 (19): 5213–5224.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1032

Published: 01 October 2021

View article

Includes: Supplementary data

Journal Articles

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, Timothy C. Thompson

Clin Cancer Res (2021) 27 (17): 4898–4909.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-1010

Published: 01 September 2021

View article

Includes: Supplementary data

Journal Articles

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Clin Cancer Res (2021) 27 (11): 3050–3060.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4118

Published: 01 June 2021

View article

Includes: Supplementary data

Journal Articles

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna Bendell

Clin Cancer Res (2021) 27 (5): 1267–1277.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-2821

Published: 01 March 2021

View article

Includes: Supplementary data

Journal Articles

Abstract IA14: Targeting the DNA damage response in head and neck cancers

Timothy A. Yap

Clin Cancer Res (2020) 26 (12_Supplement_2): IA14.

DOI: https://doi.org/10.1158/1557-3265.AACRAHNS19-IA14

Published: 15 June 2020

View article

Journal Articles

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Clin Cancer Res (2019) 25 (24): 7331–7339.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-4121

Published: 13 December 2019

View article

Includes: Supplementary data

Journal Articles

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, Mark J. O'Connor, Timothy A. Yap

Clin Cancer Res (2019) 25 (13): 3759–3771.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-0968

Published: 01 July 2019

View article

Journal Articles

Precision Oncology Decision Support: Current Approaches and Strategies for the Future

Katherine C. Kurnit, Ecaterina E. Ileana Dumbrava, Beate Litzenburger, Yekaterina B. Khotskaya, Amber M. Johnson, Timothy A. Yap, Jordi Rodon, Jia Zeng, Md Abu Shufean, Ann M. Bailey, Nora S. Sánchez, Vijaykumar Holla, John Mendelsohn, Kenna Mills Shaw, Elmer V. Bernstam, Gordon B. Mills, Funda Meric-Bernstam

Clin Cancer Res (2018) 24 (12): 2719–2731.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2494

Published: 14 June 2018

View article

Includes: Supplementary data

Journal Articles

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

Kurt W. Evans, Erkan Yuca, Argun Akcakanat, Stephen M. Scott, Natalia Paez Arango, Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, Agda K. Eterovic, Dalliah M. Black, Jennifer K. Litton, Timothy A. Yap, Debu Tripathy, Gordon B. Mills, Funda Meric-Bernstam

Clin Cancer Res (2017) 23 (21): 6468–6477.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-0615

Published: 31 October 2017

View article

Includes: Supplementary data

Journal Articles

Combining Molecularly Targeted Agents: Is More Always Better?

Raghav Sundar, Nicola Valeri, Kevin J. Harrington, Timothy A. Yap

Clin Cancer Res (2017) 23 (5): 1123–1125.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-2399

Published: 28 February 2017

View article

Journal Articles

Abstract IA10: Targeting the DNA damage response in cancer: Progress in the clinic

Timothy A. Yap

Clin Cancer Res (2017) 23 (1_Supplement): IA10.

DOI: https://doi.org/10.1158/1557-3265.PMCCAVULN16-IA10

Published: 02 January 2017

View article

Journal Articles

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Clin Cancer Res (2015) 21 (20): 4586–4596.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-0584

Published: 14 October 2015

View article

Includes: Supplementary data

Journal Articles

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Saeed Rafii, Desamparados Roda, Elena Geuna, Begona Jimenez, Karim Rihawi, Marta Capelan, Timothy A. Yap, L. Rhoda Molife, Stanley B. Kaye, Johann S. de Bono, Udai Banerji

Clin Cancer Res (2015) 21 (8): 1869–1876.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-2424

Published: 14 April 2015

View article

Includes: Supplementary data

Journal Articles

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Clin Cancer Res (2015) 21 (4): 739–748.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1901

Published: 16 February 2015

View article

Includes: Supplementary data

Journal Articles

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Clin Cancer Res (2014) 20 (22): 5672–5685.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0868

Published: 13 November 2014

View article

Includes: Supplementary data

Journal Articles

Circulating Tumor Cells: A Multifunctional Biomarker

Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, Johann S. de Bono

Clin Cancer Res (2014) 20 (10): 2553–2568.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-2664

Published: 14 May 2014

View article

Journal Articles

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

Clin Cancer Res (2013) 19 (19): 5485–5493.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-1262

Published: 01 October 2013

View article

Includes: Supplementary data

Journal Articles

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Clin Cancer Res (2013) 19 (4): 909–919.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-2258

Published: 14 February 2013

View article

Includes: Supplementary data

NARROW

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Abstract IA14: Targeting the DNA damage response in head and neck cancers

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

Precision Oncology Decision Support: Current Approaches and Strategies for the Future

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

Combining Molecularly Targeted Agents: Is More Always Better?

Abstract IA10: Targeting the DNA damage response in cancer: Progress in the clinic

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Circulating Tumor Cells: A Multifunctional Biomarker

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only